Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, talks on the management of patients with low and high-risk myelodysplastic syndromes (MDS). While the treatment of low-risk MDS is focused on improving the patient’s quality of life (QoL), high-risk MDS is usually managed like acute leukemias. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.